



“KDIGO Recommendations Make the Argument”

How KDIGO publications and
activities can help you improve local
healthcare

David Wheeler
KDIGO Co Chair

The KDIGO Mission

Improving the care and outcomes of kidney disease patients worldwide through the development and implementation of clinical practice guidelines.



Kidney Disease: Improving Global Outcomes



KDIGO's Action Agenda

- To translate scientific advances into useful and practical clinical practice recommendations.
- To make these recommendations available to clinicians around the world.
- To develop recommendations taking into account cultural, economic, language, regulatory and environmental issues.
- To adapt, simplify, prioritize and highlight recommendations to make them usable to clinicians in their everyday clinical practice



KDIGO's Action Agenda

- To translate scientific advances into useful and practical clinical practice recommendations.
- To make these recommendations available to clinicians around the world.
- To develop recommendations taking into account cultural, economic, language, regulatory and environmental issues.
- To adapt, simplify, prioritize and highlight recommendations to make them usable to clinicians in their everyday clinical practice

Published KDIGO Guidelines



Hepatitis C April 2008
Mineral Bone Disorder July 2009
Transplant Recipient Oct 2009

Acute Kidney Injury March 2012
Glomerulonephritis June 2012
Anaemia August 2012



Blood Pressure in CKD November 2012
Diagnosis and Management of CKD January 2013
Lipid Management November 2013





MARKED JOURNAL LIST

Sorted by: Impact Factor

Abbreviated Journal Title	ISSN	2014 Total Cites	Impact Factor	5-Year Impact Factor	Immediacy Index	2014 Articles	Cited Half-life	Eigenfactor [®] Score	Article Influence [®] Score
EUR UROL	0302-2838	21495	13.938	11.260	4.978	228	4.6	0.06113	3.540
KIDNEY INT SUPPL	2157-1724	691	10.435	7.533	0.000	20	2.2	0.00472	3.297
J AM SOC NEPHROL	1046-6673	32059	9.343	9.621	2.108	260	8.3	0.05942	3.376
KIDNEY INT	0085-2538	37913	8.563	7.891	2.812	245	9.5	0.05526	2.699
NAT REV NEPHROL	1759-5061	2345	8.542	7.789	1.623	53	3.1	0.01271	2.763
AM J KIDNEY DIS	0272-6386	19397	5.900	5.555	1.949	197	9.1	0.03315	1.863
NAT REV UROL	1759-4812	1405	4.840	4.759	1.109	55	3.2	0.00746	1.662
CLIN J AM SOC NEPHRO	1555-9041	10854	4.613	5.466	1.016	244	4.5	0.04195	1.878
J UROLOGY	0022-5347	46523	4.471	4.101	1.131	458	9.6	0.06601	1.268
CURR OPIN NEPHROL HY	1062-4821	2971	3.862	3.682	0.489	90	5.7	0.00784	1.196
NEPHROL DIAL TRANSPL	0931-0509	22479	3.577	3.457	1.096	332	6.6	0.04807	1.055
PROSTATE	0270-4137	7447	3.565	3.474	0.752	161	6.8	0.01370	0.942



How are KDIGO Guidelines developed?


- Rigorous, transparent and unbiased process for identifying relevant clinical trials, observational studies, meta-analyses and systematic reviews.
- Expert workgroup work with evidence review team to develop and grade clinical practice recommendations for given clinical scenarios.
- Published in international clinical journals and online at www.kdigo.org



Making best use of KDIGO Guidelines

What can we achieve by Guideline dissemination?

- Help busy clinicians make the best clinical decisions
- Improve outcomes for your patients
- Increase your patients' access to healthcare
- Streamline efficiency of healthcare delivery






Making best use of KDIGO Guidelines

With whom can you share KDIGO Guidelines?


- Colleagues
- Patients
- Health policy makers
- Payers
- Administrators
- Regulatory Authorities

KDIGO





Improving Healthcare through implementation of clinical science





Controversies Conferences

2015:

- Diabetes and CKD
- Fabry Disease
- Complement-Mediated Kidney Diseases
- Gitelman Syndrome

2014:

- ADPKD
- Iron Management in CKD
- ADTKD
- Nephropathic Cystinosis

2013:

- CKD-MBD: Back to the Future
- Supportive Care

2012:

- Diabetic Kidney Disease

2011:

- Novel Techniques & Innovation in Blood Purification

2010:

- Cardiovascular Disease in CKD
- Drug Prescribing in CKD: Initiative for Improved Dosing

2009:

- Definition, Classification, and Prognosis in CKD
- Blood Pressure in CKD - Stage 5D

2007:

- Clinical Practice Guidelines: Methodology and Transparency
- Coordination of Clinical Practice Guidelines for Anaemia in CKD

2006:

- CKD as a Global Public Health Problem
- Care of the Transplant Recipient

2005:

- Definition, Evaluation & Classification of Renal Osteodystrophy

2004:

- Definition & Classification of CKD



Controversies Conferences

- Bring together recognized experts to use collective judgment and knowledge questions:
 - “What Do We Know?”
 - “What Can We Do With What We Know?”
 - “What Don’t We Know?”
- Conference reports contain information that can be used by advocacy efforts.



Controversies conference reports

				Persistent albuminuria categories Description and range		
				A1	A2	A3
				Normal to mildly increased	Moderately increased	Severely increased
				<30 mg/g <3 mg/mmol	30–300 mg/g 3–30 mg/mmol	>300 mg/g >30 mg/mmol
GFR categories (ml/min/ 1.73 m ²) Description and range	G1	Normal or high	≥90		Monitor	Refer*
	G2	Mildly decreased	60–89		Monitor	Refer*
	G3a	Mildly to moderately decreased	45–59	Monitor	Monitor	Refer
	G3b	Moderately to severely decreased	30–44	Monitor	Monitor	Refer
	G4	Severely decreased	15–29	Refer*	Refer*	Refer
	G5	Kidney failure	<15	Refer	Refer	Refer



Controversies conference reports

<http://www.kidney-international.org>

meeting report

© 2015 International Society of Nephrology

Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Arlene B. Chapman¹, Olivier Devuyst², Kai-Uwe Eckardt³, Ron T. Gansevoort⁴, Tess Harris⁵, Shigeo Horie⁶, Bertram L. Kasiske⁷, Dwight Odland⁸, York Pei⁹, Ronald D. Perrone¹⁰, Yves Pirson¹¹, Robert W. Schrier¹², Roser Torra¹³, Vicente E. Torres¹⁴, Terry Watnick¹⁵ and David C. Wheeler¹⁶ for Conference Participants¹⁷





You Are Part of the KDIGO Global Network

900 Volunteers



Global problems – local solutions



KDIGO Global Network

The Global Network helps KDIGO to:

- Communicate with the kidney community and health policy makers around the world.
- Disseminate KDIGO guidelines and conference reports to policy makers.
- Incorporate education on KDIGO Guidelines into local symposia.
- Analyze local health care environments to learn how best to use KDIGO recommendations to influence policy decisions.



What is KDIGO doing next?

- New Guidelines
- Guideline updates
- Living Guidelines
- Comprehensive database of RCTs
- Controversies Conferences
- Computerised tools
- Implementation activities



New in 2015: Living Donor Guideline



Guideline Co-Chairs

Amit Garg
Canada

Krista Lentine
USA

Evidence Review Center for this guideline is the AHRQ Center at the University of Minnesota. This guideline is being written in collaboration with The Transplantation Society (TTS). It will cover the care, selection, risk assessment and prognosis of the living kidney donor.

TTS Representatives

Patricia Adams
USA

Lorenzo Gallon
USA

Work Group Members

Josefina Alberu
Mexico

Mohamed Bakr
Egypt

Josep Campistol
Spain

Cathy Garvey
USA

Sandeep Gularia
India

Andrew Levey
USA

Philip K. T. Li
Hong Kong

Jose Osmar Medina-Pestana
Brazil

Dorry Segev
USA

Faissal Shaheen
Saudi Arabia

Sandra Taler
USA

Kazunari Tanabe
Japan

Linda Wright
Canada

Martin Zeier
Germany

Coming Soon: Transplant Candidate Guideline

KDIGO's next new guideline, tentatively entitled "**KDIGO Clinical Practice Guideline for the Evaluation and Management of Candidates for Kidney Transplantation**", will focus on selection of kidney transplant recipients.

Guideline Co-Chairs

Greg Knoll
Canada

Steve J. Chadban
Australia

KDIGO will work again with The Transplantation Society (TTS) on this original guideline, continuing the collaborative relationship forged during development of the KDIGO Guideline on The Evaluation and Follow Up Care of Living Kidney Donors.



Published KDIGO Guidelines



Hepatitis C April 2008
Mineral Bone Disorder July 2009
Transplant Recipient Oct 2009

Acute Kidney Injury March 2012
Glomerulonephritis June 2012
Anaemia August 2012




Blood Pressure in CKD November 2012
Diagnosis and Management of CKD January 2013
Lipid Management November 2013





Guideline Updates in Progress




Co-chair: Mary Leonard, USA

Co-chair: Markus Ketteler, Germany

Co-chair: Michel Jadoul, Belgium

Co-chair: Paul Martin, USA



Diabetes & CKD Conference

2015



- Addressed issues pertinent to the management of diabetes in the context of CKD.
- Co-chairs: Vlado Perkovic, Australia & Per-Henrik Groop, Finland
- Date: February 5-8, 2015
- Location: Vancouver, Canada



Rare Kidney Diseases Conference Series

The Rare Kidney Diseases Conference Series will focus on six rare diseases and culminate in a major Controversies Conference in early 2016. The series will frame new questions, explore treatment options, and help shape the global research agenda.

Rare Kidney Diseases Conference Series Topics:

- Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD)
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Nephropathic Cystinosis
- Fabry Disease
- Complement-Mediated Kidney Diseases
- Gitelman Syndrome



Common Elements in Uncommon Kidney Diseases

2016

- This meeting will focus on clinical issues common to all rare kidney conditions such as referral, genetic counseling, centers of excellence, progression from pediatric to adult care, and registries.
- Co-Chairs: Olivier Devuyst, Switzerland & Lisa Guay-Woodford, USA
- Date: April 2016





Challenges in Clinical Trials in Nephrology

2016

- Will bring together sponsors, scientists, trialists and patients to debate and discuss controversial issues related to trial design and the impact of trials on patient care.
- Co-chairs: Colin Baigent, England and John McMurray, Scotland
- Topics will include:
 - Reasons for the failures of RCTs in nephrology
 - Optimal clinical trial design
 - Relevant clinical endpoints
 - The role of trial consortia
 - Secondary analysis and meta-analysis trials
 - Innovations that reduce the cost of clinical trials
 - The use of registries to capture endpoints



Total Care in the transition from Stage 4-5

December 2016

- Dataset assembled and analyzed by the CKD Prognosis
- Co-chairs: Brenda Hemmelgarn, Canada and Kai-Uwe Eckardt, Germany
- The conference will address why many patients in Stage 4 do not receive kidney replacement therapy.
 - If they die, what do they die of?
 - As they progress how are major co-morbidities managed?
 - How often is supportive care used?
 - How does care in Stage 4 determine outcomes in Stage 5?
 - How are patients and families involved in care?
 - How are the treatment needs of patients at both stages handled to maximize outcomes?



2015 Clinical Practice Conferences



February 9 – Mumbai, India
4th Annual Mumbai Nephrology Summit


February 10 – Calabar, Nigeria
27th Annual Nigerian Association of Nephrology
General Meeting and Scientific Conference



February 24-27 – Cairo, Egypt
33rd Annual ESNT Conference

June 5-7 – Nagoya, Japan
58th Japanese Society of Nephrology Meeting

September 15-19 – St. Petersburg, Russia
Renal Week 2015 in collaboration with the Russian
Dialysis Society



September 17-19 – Daegu, Korea
7th Asia Pacific Chapter Meeting of International
Society for Peritoneal Dialysis, in collaboration with the
Korean Society of Nephrology



Expert Roundtables

A gathering of local, regional or international KDIGO experts. They discuss specific questions or topics presented by a KDIGO corporate partner.

Topics can include:

- Reimbursement policies and challenges
- Regulatory issues
- Regional practice patterns
- Physician education needs
- Value of KDIGO clinical recommendations
- Competitive environment



Expert Roundtables can be sponsored. They are sometimes held in conjunction with country or regional congresses, or can be stand alone events.



Now available for iPad & iPhone



Download the *KDIGO Clinical Practice Guidelines for Kidney Disease* app today. Access the complete library of KDIGO guidelines on your *iPad & iPhone* for free.



Summary



- KDIGO translates high quality evidence into clinical practice recommendations.
- Controversies conferences highlight gaps in knowledge and highlight areas where research is needed.
- KDIGO publications can be used to influence those who developed healthcare policy.
- KDIGO activities can provide opportunities to engage policy makers.
- KDIGO wants to learn from its implementation efforts to become more effective in its mission.

FOLLOW KDIGO



www.kdigo.org



@goKDIGO



@goKDIGO



@goKDIGO



Examples of KDIGO Recommendations You Can Use to Influence Policy Decisions

- KDIGO Guideline recommendations on specific treatments:
 - Anemia, target Hbg levels
 - Bone and Mineral Disorders, the nomenclature itself
 - Lipids Management, use and keep patients on statins
 - Blood Pressure, lower levels improve CVD risk
- KDIGO Controversies Conference recommendations:
 - Stages of CKD, based on eGFR
 - “Heat Map” of risk of progression based on eGFR and Albuminuria to Creatinine Ratio
 - Appropriate iron therapy in anemia management
 - Diabetes with CKD means more than glucose management